Disease · MONDO_0005310

atrial flutter

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. atrial flutter. Diseases, record MONDO_0005310. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005310

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: atrial flutter; Open Targets
Open Targets ID: MONDO_0005310; Open Targets
Other names: Atrial Flutters, Auricular Flutter, Auricular Flutters, Flutter, Atrial, Flutter, Auricular, Flutters, Atrial, Flutters, Auricular, atrial flutter (disease); Open Targets
MeSH: D001282; MeSH
NCI Thesaurus: C51224; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 24 drugs, from FDA; Open Targets

Drugs24

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LANDIOLOL HYDROCHLORIDE	CHEMBL2362410	Small molecule	Approval	FDA	2	0	0	Drugs and targets
DOFETILIDE	CHEMBL473	Small molecule	Approval	EMA Human Drugs, at withdrawal	1	0	0	Drugs and targets
AMIODARONE	CHEMBL633	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
TEDISAMIL SESQUIFUMARATE	CHEMBL2107378	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
DRONEDARONE	CHEMBL184412	Small molecule	Phase 3	ClinicalTrials.gov	3	2	2	Drugs and targets
SOTALOL	CHEMBL471	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
VANOXERINE	CHEMBL281594	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
VERNAKALANT	CHEMBL2111112	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
VERNAKALANT HYDROCHLORIDE	CHEMBL2107383	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
AZIMILIDE DIHYDROCHLORIDE	CHEMBL3140370	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 24

See all 24 drugs

Targets37

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KCNH2	Voltage-gated inwardly rectifying potassium channel KCNH2	5	HERG blocker	Approval	https://conductscience.org/library/genes/3757	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	4	Beta-1 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/153	Drugs and targets
SCN5A	Sodium channel alpha subunit	4	Sodium channel alpha subunit blocker; Sodium channel protein type V alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6331	Drugs and targets
CACNA1C	Voltage-gated L-type calcium channel	2	Voltage-gated L-type calcium channel blocker	Phase 3	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated L-type calcium channel	2	Voltage-gated L-type calcium channel blocker	Phase 3	https://conductscience.org/library/genes/776	Drugs and targets
CACNA1F	Voltage-gated L-type calcium channel	2	Voltage-gated L-type calcium channel blocker	Phase 3	https://conductscience.org/library/genes/778	Drugs and targets
CACNA1S	Voltage-gated L-type calcium channel	2	Voltage-gated L-type calcium channel blocker	Phase 3	https://conductscience.org/library/genes/779	Drugs and targets
F10	Coagulation factor X	2	Coagulation factor X inhibitor	Phase 2	https://conductscience.org/library/genes/2159	Drugs and targets
KCNA5	Potassium voltage-gated channel subfamily A member 5	2	Voltage-gated potassium channel subunit Kv1.5 blocker	Phase 3	https://conductscience.org/library/genes/3741	Drugs and targets
KCND3	A-type voltage-gated potassium channel KCND3	2	Voltage-gated potassium channel subunit Kv4.3 blocker	Phase 3	https://conductscience.org/library/genes/3752	Drugs and targets

1 to 10 of 37

See all 37 targets

Trials24

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02132767	Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation	Phase 3	523	2017-01-18	Postoperative Atrial Fibrillation	AMIODARONE	Its record names the disease	ClinicalTrials.gov
NCT01229254	Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter	Phase 2	189	2017-09-18	Atrial Fibrillation, Atrial Flutter	BETRIXABAN	Its record names the disease	ClinicalTrials.gov
NCT01691313	Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm	Phase 2	104	2015-12-22	Symptomatic Atrial Fibrillation, Atrial Flutter	VANOXERINE	Its record names the disease	ClinicalTrials.gov
NCT02454283	Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm	Phase 3	41	2016-10-17	Atrial Fibrillation or Flutter	VANOXERINE	Its record names the disease	ClinicalTrials.gov
NCT00007605	Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm	Phase 3	706		Atrial Fibrillation, Cerebrovascular Accident, Death, Sudden	AMIODARONE, SOTALOL	Its record names the disease	ClinicalTrials.gov
NCT00233441	Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter	Phase 2/3	673		Atrial Fibrillation, Atrial Flutter	CELIVARONE	Its record names the disease	ClinicalTrials.gov
NCT00259376	American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm	Phase 3	629		Atrial Fibrillation, Atrial Flutter	DRONEDARONE	Its record names the disease	ClinicalTrials.gov
NCT00259428	EURopean Trial In Atrial Fibrillation(AF) or Flutter (AFL) Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)	Phase 3	615		Atrial Fibrillation, Atrial Flutter	DRONEDARONE	Its record names the disease	ClinicalTrials.gov
NCT00691470	Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation	Phase 2/3	600		Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction, Cardiomyopathy	TECARFARIN SODIUM, WARFARIN	Its record names the disease	ClinicalTrials.gov
NCT00035477	Efficacy and Safety of Azimilide for the Treatment of Patients With Atrial Fibrillation	Phase 3	446		Atrial Fibrillation	AZIMILIDE DIHYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 24

See all 24 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Rate Control vs Rhythm Control: serious adverse events	71 of 262	73 of 261	523	NCT02132767	Trial comparisons
Rate Control vs Rhythm Control: Heart Rhythm Comparison	231 of 257	244 of 261	518	NCT02132767	Trial comparisons
Rate Control vs Rhythm Control: Heart Rhythm Comparison	220 of 242	223 of 248	490	NCT02132767	Trial comparisons
Rate Control vs Rhythm Control: Heart Rhythm Comparison	220 of 234	231 of 236	470	NCT02132767	Trial comparisons
Vanoxerine HCl vs Placebo: Conversion to Sinus Rhythm	18 of 26	3 of 15	41	NCT02454283	Trial comparisons
Vanoxerine HCl vs Placebo: serious adverse events	4 of 26	0 of 15	41	NCT02454283	Trial comparisons

Papers from its trials23

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36402632	RESULT	1	PubMed
35623182	RESULT	1	PubMed
33461700	RESULT	1	PubMed
32745920	RESULT	1	PubMed
25913166	RESULT	1	PubMed
25684233	RESULT	1	PubMed
24685669	RESULT	1	PubMed
23468405	RESULT	1	PubMed
22171925	RESULT	2	PubMed
22032709	RESULT	1	PubMed

1 to 10 of 23

See all 23 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005310

GET https://conductscience.org/api/diseases/v1/MONDO_0005310/drugs?page=2

API reference For AI assistants